Exagen (XGN) AI Stock Analysis

• Market Cap: $72.64M
• Dividend Yield: N/A
• Average Volume (3M): 366.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.03
• Revenue Growth: 14.08%
• EPS Growth: 1.34%
• Country: US
• Employees: 209
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.20
• Shares Outstanding: 24,053,059
• 10 Day Avg. Volume: 375,981
• 30 Day Avg. Volume: 365,999
• PEG Ratio: -0.55
• Price to Book (P/B): 7.51
• Price to Sales (P/S): 1.97
• P/FCF Ratio: -9.19
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: 0.96
• Enterprise Value/Gross Profit: 1.64
• Enterprise Value/Ebitda: -5.33
• 1Y Price Target: $9.50
• Price Target Upside: 199.68% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -0.48
• Revenue Forecast (FY): $73.85M

• Rating: 44 Neutral
• Price Target: $3.50 ▲(10.41% Upside)
• Action: Reiterated Date: 03/10/26
• Date: Action: Reiterated 03/10/26

The score is held down primarily by weak financial performance (continued net losses and ongoing cash burn despite improving debt/equity) and bearish technicals (price below key moving averages with negative MACD). The latest earnings commentary is more constructive on growth and a potential path to cash-flow positivity, but near-term ASP and expense pressures keep the outlook mixed, while valuation is difficult to support with a negative P/E and no dividend data.

Positive Factors

Revenue & Volume Growth

Sustained revenue and volume expansion indicate growing clinical adoption of AVISE tests. Durable 2025 momentum (record quarter, YTD growth) supports scale economics, strengthens bargaining power with payors, and improves the probability of reaching sustained profitability once ASP and expense trends stabilize.

Product Expansion / Differentiation

Introducing new biomarkers broadens clinical utility and differentiates Exagen's AVISE platform. Durable product innovation can deepen clinician reliance, justify higher reimbursement over time, and create barriers to entry in autoimmune diagnostics if supported by outcomes and payer coverage.

Improving Balance Sheet & Liquidity

Material debt reduction and a larger equity base materially lower refinancing and solvency risk, extending runway. Stronger liquidity and asset growth provide capacity to invest in commercial expansion, R&D, and appeals infrastructure critical to securing durable reimbursement gains.

Negative Factors

Persistent Cash Burn

Ongoing negative operating and free cash flow demonstrates structural cash consumption. Continued reliance on financing or balance sheet reserves raises execution risk, constrains strategic flexibility, and makes achievement of durable growth dependent on converting revenue momentum into operating cash generation.

Sustained Unprofitability

Persistent operating losses despite revenue gains indicate that operating costs and investment cadence outpace gross profit expansion. Until operating leverage is achieved, profitability is uncertain, limiting reinvestment capacity and increasing sensitivity to reimbursement or volume setbacks.

Reimbursement / ASP Headwinds

Dependence on reimbursement mix and ASP creates durable revenue risk: payer denials and account mix shifts reduce realized price per test. These structural reimbursement challenges can delay cash-flow breakeven and require sustained revenue cycle and payer engagement investments to restore pricing.

Exagen Business Overview & Revenue Model

Company Description

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

How the Company Makes Money

Exagen makes money primarily by performing its proprietary autoimmune diagnostic tests as a clinical laboratory service and recognizing revenue when those tests are ordered by healthcare providers and processed by Exagen. The core revenue stream is test service revenue generated per patient specimen (i.e., payment for completed tests), with cash collection dependent on reimbursement from third-party payors (commercial insurers and government programs) and, in some cases, direct patient responsibility. The company’s earnings are therefore influenced by test volume (ordering adoption by rheumatologists and other clinicians), achieved reimbursement rates and coverage decisions by payors, the mix of payors (commercial vs. government), billing and collections performance (including denials and appeals), and the company’s ability to maintain/expand clinical utility evidence and contracting needed to support reimbursement. Information about any material revenue contribution from partnerships, licensing, or non-testing product sales is null.

Exagen Financial Statement Overview

Summary

Revenue is growing and losses have narrowed versus 2022, and leverage improved meaningfully with sharply lower debt and higher equity. However, the company remains unprofitable with persistent operating losses, and operating/free cash flow are negative across all periods shown, keeping financial quality weak.

Income Statement

Revenue has grown steadily over the last several years, accelerating in the most recent annual period (2025 revenue up ~4.7% vs. ~5.9% in 2024 and ~15.3% in 2023). Profitability is improving versus the deep losses in 2022 (net loss narrowed materially from about -$47.4M in 2022 to -$23.7M in 2023 and -$15.1M in 2024), but the business remains unprofitable with negative operating income and net income in every year provided (2025 net loss ~-$20.0M). Gross profit dollars are expanding, yet operating costs still outweigh gross profit, keeping margins meaningfully negative and limiting the score.

Balance Sheet

Leverage appears to be improving meaningfully: total debt fell sharply to ~$5.4M in 2025 from ~$23.0M in 2024, while equity increased to ~$17.4M from ~$9.5M. Total assets also grew to ~$58.0M in 2025 from ~$44.7M in 2024. However, returns remain weak given ongoing net losses (negative returns on equity in the years provided), and the equity base has been volatile over time, which keeps the balance sheet assessment in the middle rather than strong.

Cash Flow

Cash burn remains a key issue: operating cash flow and free cash flow are negative every year shown. While free cash flow improved materially in 2025 (to about -$14.3M vs. -$13.8M in 2024 and -$15.3M in 2023, and far better than 2022’s -$36.5M), the company is still not generating cash from operations, implying continued reliance on financing and/or balance sheet resources to fund losses.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	66.58M	55.64M	52.55M	45.56M	48.30M
Gross Profit	38.80M	33.11M	29.46M	21.35M	27.71M
EBITDA	-11.95M	-11.14M	-19.15M	-43.66M	-23.10M
Net Income	-19.95M	-15.12M	-23.69M	-47.39M	-26.85M
Balance Sheet
Total Assets	58.02M	44.69M	56.94M	86.22M	123.44M
Cash, Cash Equivalents and Short-Term Investments	32.22M	22.04M	36.49M	62.39M	99.44M
Total Debt	5.40M	23.00M	23.23M	35.20M	28.07M
Total Liabilities	40.57M	35.15M	34.25M	43.76M	38.51M
Stockholders Equity	17.45M	9.54M	22.69M	42.46M	84.94M
Cash Flow
Free Cash Flow	-14.27M	-13.79M	-15.29M	-36.46M	-22.64M
Operating Cash Flow	-13.63M	-13.28M	-14.46M	-32.14M	-20.27M
Investing Cash Flow	-626.00K	-515.00K	-804.00K	-4.32M	-2.42M
Financing Cash Flow	24.43M	-663.00K	-10.63M	-489.00K	64.68M

Exagen Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XGN, the sentiment is Negative. The current price of 3.17 is below the 20-day moving average (MA) of 3.38, below the 50-day MA of 3.97, and below the 200-day MA of 7.52, indicating a bearish trend. The MACD of -0.25 indicates Negative momentum. The RSI at 34.11 is Neutral, neither overbought nor oversold. The STOCH value of 23.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XGN.

Exagen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRE	61 Neutral	$344.31M	-3.79	-36.02%	―	159.45%	8.59%
ACRS	52 Neutral	$441.38M	-4.66	-113.23%	―	-41.87%	-165.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
STIM	47 Neutral	$93.52M	-2.33	-138.87%	―	78.62%	32.39%
SERA	47 Neutral	$73.72M	-4.40	-47.69%	―	1.06%	22.41%
MDXH	46 Neutral	$161.86M	-5.33	516.59%	―	21.68%	58.30%
XGN	44 Neutral	$72.64M	-6.57	-126.62%	―	14.08%	1.34%

Exagen Corporate Events

Exagen Announces Record 2025 Revenue and Strong Cash Position

On January 11, 2026, Exagen Inc. reported select preliminary unaudited results for the fourth quarter and full year ended December 31, 2025, indicating record annual revenue of $66 million to $67 million, up 19% to 20% year over year, with fourth-quarter revenue projected at $16 million to $17 million, a 17% to 24% increase. The company highlighted continued momentum in its AVISE CTD franchise, with 2025 test volumes rising to 136,000 to 137,000, an 11% increase over 2024, and a trailing 12‑month average selling price of $441 to $445, at least $30 higher than the prior year, despite pricing headwinds in the second half. Year-end cash and cash equivalents improved to $32 million, about $10 million higher than at the end of 2024, underscoring stronger liquidity as Exagen ramps investment in scientific and commercial capabilities and rolls out enhancements to its AVISE platform, moves that reinforce its competitive positioning in autoimmune diagnostics while management continues to target a path to profitability.

The most recent analyst rating on (XGN) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Exagen stock, see the XGN Stock Forecast page.